title: Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man.
abstract: The newly discovered intestinal hormone, glucagon-like peptide-1 (GLP-1) (proglucagon 78-107amide), stimulates insulin secretion and inhibits glucagon secretion in man and may therefore be anticipated to influence hepatic glucose production. To study this, we infused synthetic GLP-1 sequentially at rates of 25 and 75 pmol.kg-1.h-1 into eight healthy volunteers after an overnight fast and measured plasma concentrations of glucose, insulin, and glucagon and glucose turnover by a technique involving infusion of 3-3H-glucose. Plasma levels of GLP-1 increased by 21.3 +/- 3.1 and 75.4 +/- 3.2 pmol/L during the infusion, changes that were within physiologic limits. In a control experiment only saline was infused. During GLP-1 infusion, plasma glucose level decreased significantly (from 5.3 +/- 0.1 to 4.7 +/- 0.1 and 4.3 +/- 0.1 pmol/L at the end of the two infusion periods). Despite this, plasma insulin level increased significantly (from 20.5 +/- 2.9 to a peak value of 33.5 +/- 5.2 pmol/L during the second period), and plasma glucagon level decreased (from 9.3 +/- 1.7 to 7.1 +/- 1.0 pmol/L). Glucose rate of appearance (Ra) decreased significantly to 75% +/- 6% of the preinfusion values during GLP-1 infusion. Glucose disappearance rate (Rd) did not change significantly, but glucose clearance increased significantly compared with saline. All parameters of glucose turnover remained constant during saline infusion. We conclude that GLP-1 may potently control hepatic glucose production and glucose clearance through its effects on the pancreatic glucoregulatory hormones. The effect of GLP-1 on glucose production is consistent with its proposed use in the treatment of type II diabetes.
authors.affiliation: Department of Endocrinology, Hvidovre Hospital, Copenhagen, Denmark.
authors.forename: A
authors.initials: A
authors.lastname: Hvidberg
authors.forename: M T
authors.initials: MT
authors.lastname: Nielsen
authors.forename: J
authors.initials: J
authors.lastname: Hilsted
authors.forename: C
authors.initials: C
authors.lastname: Orskov
authors.forename: J J
authors.initials: JJ
authors.lastname: Holst
mesh_terms: D000328:Adult; D001786:Blood Glucose / Q000032:analysis; D005934:Glucagon / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D052216:Glucagon-Like Peptide 1; D005947:Glucose / Q000378:metabolism*; D006801:Humans; D007328:Insulin / Q000097:blood / Q000378:metabolism; D008099:Liver / Q000378:metabolism*; D008297:Male; D010446:Peptide Fragments / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D011498:Protein Precursors / Q000097:blood / Q000378:metabolism / Q000494:pharmacology*; D011863:Radioimmunoassay
chemical_list: D001786:Blood Glucose; D007328:Insulin; D010446:Peptide Fragments; D011498:Protein Precursors; D052216:Glucagon-Like Peptide 1; D005934:Glucagon; D005947:Glucose